WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584444
CAS#: 1629268-00-3
Description: ARS-853 is a selective, covalent KRAS(G12C) inhibitor that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.
Hodoodo Cat#: H584444
Name: ARS-853
CAS#: 1629268-00-3
Chemical Formula: C22H29ClN4O3
Exact Mass: 432.19
Molecular Weight: 432.949
Elemental Analysis: C, 61.03; H, 6.75; Cl, 8.19; N, 12.94; O, 11.09
Synonym: ARS-853; ARS853; ARS 853
IUPAC/Chemical Name: 2-Propen-1-one, 1-[3-[4-[2-[[4-chloro-2-hydroxy-5-(1-methylcyclopropyl)phenyl]amino]acetyl]-1- piperazinyl]-1-azetidinyl]-
InChi Key: IPFOCHMOYUMURK-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H29ClN4O3/c1-3-20(29)27-13-15(14-27)25-6-8-26(9-7-25)21(30)12-24-18-10-16(22(2)4-5-22)17(23)11-19(18)28/h3,10-11,15,24,28H,1,4-9,12-14H2,2H3
SMILES Code: C=CC(N1CC(N2CCN(C(CNC3=CC(C4(C)CC4)=C(Cl)C=C3O)=O)CC2)C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 432.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
[1] Patricelli MP, et al. Cancer Discov. 2016, 6(3):316-29.
[2] Lito P, et al. Science. 2016, 351(6273):604-8.